EMEA-001441-PIP03-17-M02
Key facts
Invented name |
Ozempic
|
Active substance |
semaglutide
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/0461/2021
|
PIP number |
EMEA-001441-PIP03-17-M02
|
Pharmaceutical form(s) |
Solution for injection in pre-filled pen
|
Condition(s) / indication(s) |
Treatment of obesity
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Novo Nordisk A/S
E-mail: paediatrics@novonordisk.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|